BE545007A - - Google Patents
Info
- Publication number
- BE545007A BE545007A BE545007DA BE545007A BE 545007 A BE545007 A BE 545007A BE 545007D A BE545007D A BE 545007DA BE 545007 A BE545007 A BE 545007A
- Authority
- BE
- Belgium
- Prior art keywords
- ethyl
- dosage
- tablets
- preparation according
- phenylhydantoin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002082 anti-convulsion Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000008014 pharmaceutical binder Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010010947 Coordination abnormal Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 208000016290 incoordination Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- NXQJDVBMMRCKQG-UHFFFAOYSA-N 5-phenylimidazolidine-2,4-dione Chemical compound O=C1NC(=O)NC1C1=CC=CC=C1 NXQJDVBMMRCKQG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE545007A true BE545007A (enrdf_load_stackoverflow) |
Family
ID=172795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE545007D BE545007A (enrdf_load_stackoverflow) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE545007A (enrdf_load_stackoverflow) |
-
0
- BE BE545007D patent/BE545007A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0349235B1 (en) | Niacin and guar-gum containing composition | |
| BE1015217A5 (enrdf_load_stackoverflow) | ||
| CA2123232C (fr) | Compositions pharmaceutiques a base d'ebastine ou de ses analogues | |
| MX2010011701A (es) | Formulacion liquida para deferiprona con gusto agradable al paladar. | |
| FR2616329A1 (fr) | Nouvelles compositions laxatives et leur procede d'obtention | |
| CA1103154A (fr) | Compositions pharmaceutiques renfermant des derives organiques de la montmorillonite | |
| BE545007A (enrdf_load_stackoverflow) | ||
| BE1000265A3 (fr) | Nouvelle association medicamenteuse. | |
| BE1011385A3 (fr) | Utilisation d'un agent chimique pour diminuer les variations du tour de taille et l'effet de constipation lie a la prise d'autres agents. | |
| LU85242A1 (fr) | Nouvelle association medicamenteuse | |
| BE1004243A3 (fr) | Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation. | |
| US5627152A (en) | Method for increasing bodyweight | |
| CA2822213C (en) | Combination and composition for treating obesity | |
| JPS6081127A (ja) | 食欲抑制剤 | |
| US3639597A (en) | Pharmaceutical compositions containing cholanic acid conjugates | |
| US3495005A (en) | Compositions and methods for suppressing appetite with combinations of amphetamine and thioridazine | |
| CA1227136A (fr) | Compositions pharmaceutiques contenant a titre de principe actif l'acide 4-(benzofuran-2-yl)4-oxo buten-2-oique et/ou de ses sels pharmaceutiquement acceptables | |
| BE566423A (enrdf_load_stackoverflow) | ||
| US20050256088A1 (en) | Pharmaceutical nitrones | |
| TW200539859A (en) | Methods for increasing neurotransmitter levels using hydroxycitric acid | |
| FR2691630A1 (fr) | Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1. | |
| BE632520A (enrdf_load_stackoverflow) | ||
| FR2566664A1 (fr) | Composition utile au traitement de la diarrhee contenant du dextromethorphan | |
| BE563436A (enrdf_load_stackoverflow) | ||
| JPH07233081A (ja) | 抗高血圧組成物 |